Background and Aims

Fast‐acting insulin aspart (fAsp) is a faster‐acting insulin with a more rapid rate of absorption and greater early‐glucose‐lowering effect than conventional insulin (iAsp).

The aim of this study was to assess the postprandial glycemic control in patients with sensor-augmented pump therapy after one month of treatment with fAsp.

Methods

Five patients (2males) treated with sensor-augmented pump therapy (at least 6 months prior to the initiation of fAsp) whose age were 41±11 years and basal HbA1c 7,1±0,4%, were included.

Episodes of postprandial hyperglycemia (>140 mg/dL) were analysed before and after one-month treatment with fAsp. Other variables analysed were the area under the curve (AUC) >140 mg/dL, AUC <70 mg/dL, mean glucose and standard deviation (mg/dL), total insulin dose (IU/day) and basal/bolus distribution (%).

Results

Postprandial hyperglycemia episodes (>140 mg/dL) were reduced by 9.1% after one month of treatment with fAsp.

The continuous glucose monitoring results are shown in the following table:

Conclusions

After one-month follow-up with fAsp, hyperglycemia events decreased without increasing the time in hypoglycemia and without changes in the basal/bolus distribution, in patients with sensor-augmented pump therapy.